Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medpace Holdings's EBIT per Share for the
three
months ended in Jun. 2026 was MXN89.72.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 was MXN363.33.
During the past 12 months, the average EBIT per Share Growth Rate of Medpace Holdings was 31.40% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 29.80% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 33.90% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 35.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Medpace Holdings's EBIT per Share or its related term are showing as below:
MEX:MEDP'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -2 Med: 33.7 Max: 53.7
Current: 29.8
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Medpace Holdings was 53.70% per year. The lowest was -2.00% per year. And the median was 33.70% per year.
MEX:MEDP's 3-Year EBIT Growth Rate is ranked better than 67.27% of 165
companies
in the Medical Diagnostics & Research industry
Industry Median: 13.2
vs MEX:MEDP: 29.80
Medpace Holdings's EBIT for the
three
months ended in Jun. 2026 was MXN2,562 Mil.
Medpace Holdings (MEX:MEDP) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Medpace Holdings EBIT per Share Related Terms
Medpace Holdings EBIT per Share Historical Data
* Premium members only.
The historical data trend for Medpace Holdings's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN363.33
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medpace Holdings (MEX:MEDP) has a EBIT per Share of MXN363.33 as of Jun. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Medpace Holdings and its competitors. According to the industry distribution chart, Medpace Holdings ranks #54 out of 165 companies in the Medical Diagnostics & Research industry, placing it in the top 32.7%.
Is Medpace Holdings' EBIT per Share too high?
Medpace Holdings' current EBIT per Share is MXN363.33. Based on the distribution chart, Medpace Holdings ranks #54 out of 165 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Medpace Holdings has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' EBIT per Share compare to ICLR and RVTY?
According to the Medical Diagnostics & Research industry distribution chart, Medpace Holdings ranks #54 out of 165 companies for EBIT per Share. This puts Medpace Holdings in the upper half of its industry. The industry median EBIT per Share is 13.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 13.20, based on 165 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Medpace Holdings and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 13.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medpace Holdings's current EBIT per Share is MXN363.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Medpace Holdings (MEX:MEDP) has a current EBIT per Share of MXN363.33. The stock's GF Value™ is MXN6,131.53, compared to a current price of MXN7,022.03 — trading 14.5% above its estimated fair value. The current EBIT per Share is MXN363.33. Medpace Holdings' overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Medpace Holdings (MEX:MEDP), the current EBIT per Share is MXN363.33 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medpace Holdings (MEX:MEDP) Overvalued in 2026?
Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued.
The current stock price of MXN7,022.03 is trading 14.5% above its estimated GF Value™ of MXN6,131.53.
Key valuation signals for MEX:MEDP:
EBIT per Share: MXN363.33
GF Value™: MXN6,131.53 vs. price of MXN7,022.03 (14.5% above fair value)
No single metric tells the full story. See the MEX:MEDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
95GF Score
Get the complete analysis for MEX:MEDP
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:MEDP has been successfully added to your 
